Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect Study of Talazoparib Formulations in Advanced Solid Tumors
NCT04672460Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of talazoparib in solid tumor (advanced stage) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours, Maximum Observed Plasma Concentration and 2 more. Started Dec 2020; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04672460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672460.